SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 26, 2002
-----------------
Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-16005 22-2328609
-------- ------- ----------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
110 Little Falls Road, Fairfield, NJ 07004
- ---------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (973) 882-0860
N/A
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events.
Unigene Laboratories, Inc., a Delaware corporation ("Unigene"), and Upsher-Smith
Laboratories, Inc., a Minnesota corporation ("USL"), have entered into a License
and Development Agreement, dated as of November 26, 2002 (the "License
Agreement"), which provides for the marketing, distribution and sale by USL of a
nasally administered salmon calcitonin pharmaceutical product developed by
Unigene for the treatment of osteoporosis in humans.
The License Agreement and the press release dated December 2, 2002, issued in
connection with the execution of the License Agreement, are filed as exhibits to
this report and are incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits.
Exhibit No. Description of Exhibit
----------- ----------------------
10.1 License and Development Agreement, dated as
of November 26, 2002, by and between Unigene
Laboratories, Inc. and Upsher-Smith
Laboratories, Inc.*
99.1 Press Release of Unigene Laboratories, Inc.
dated December 2, 2002
_____________
* Portions of the document have been omitted pursuant to a confidential
treatment request.
SIGNATURE
Pursuant to the requirements of the Signature Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
Unigene Laboratories, Inc.
By: /s/ Warren P. Levy
-------------------------------------
Warren P. Levy, President
(Chief Executive Officer)
Dated: January 9, 2003